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Diabetes mellitus has emerged as a common comorbidity in cystic ﬁbrosis and is considered a clinical entity (cystic ﬁbrosis-related diabetes,
CFRD) distinct from that of type 1 diabetes (T1DM) and type 2 diabetes (T2DM). The relevance of this diagnosis extends not only from its
imposition of additional medical burden but its association with worse health outcomes in individuals with CF. This paper will review the 2010
U.S. and other international guidelines for screening and treating CFRD. It will highlight newer data regarding early glucose and insulin secretion
defects, mechanisms linking CFRD to worse outcomes, and recent advances in T2DM that may provide insights for CFRD; insulin secretion will
be reviewed as background for these recent developments.
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1.1. Insulin physiology
Pancreatic β-cell insulin secretion strictly governs glucose,
amino acid, and fat disposition. A highly anabolic agent, insulin
targets these fuels for storage [1], stimulating glycogen synthesis
and glucose uptake by fat and muscle while suppressing hepatic
glycogenolysis and gluconeogenesis, lipolysis, and ketogenesis.
In the absence of nutrient ingestion, insulin secretion is down-
regulated and a catabolic state is invoked whereby glucose is
accessed from glycogen and through conversion from amino
acids. With more prolonged fasting, lipolysis and ketogenesis
provide alternate fuels.
Insulin secretion is regulated by the availability of nutrients,
other hormones, and neural factors. Following oral glucose
ingestion, insulin levels normally rise within the first 30 min,
peak at about 60 min, and return to baseline levels by 2–3 h. In
contrast, following intravenous glucose bolus, insulin secretion
occurs in a biphasic manner. An early rapid peak (acute insulin
response, first phase insulin secretion) occurs within the first
10 min and then a more slow increase in insulin secretion
(second phase insulin secretion) occurs over the next 20 min
(reviewed in [2]). Insulin secretion in response to oral glucose
is greater than insulin secretion in response to the same amount
of glucose delivered intravenously. This augmented response
arises from incretin secretion from gastrointestinal tract neuroen-
docrine cells in response to nutrient ingestion, Fig. 1. This
“incretin” effect may account for 50–70% of total insulinNutrient Ingestion
Carbohydrates (glucose, fructose)
Lipids FFA
Proteins amino acids
*animal models
-cell
glucagon secretion
Delayed gastric 
emptying
Fig. 1. Incretin secretion and action. Glucose, fructose, free fatty acids, and to a le
augment glucose stimulated insulin secretion and in animal models inhibit β-cell ap
suppresses glucagon secretion and delays gastric emptying.response to an oral glucose load, with glucagon-like peptide
(GLP-1) and gastric inhibitory peptide (GIP) accounting for
~90% of this response [3]. Fat also stimulates GLP-1 and GIP
secretion — an effect that requires hydrolysis of fat [4].
1.2. Diabetes classification/clinical features
The pathophysiology of diabetes development, particularly
in the setting of T2DM, is complex, but ultimately all diabetes
arises as a result of either an absolute or relative insulin-deficient
state. The American Diabetes Association (ADA) classifies
diabetes mellitus based upon etiology [5], Table 1. T1DM arises
from β-cell destruction, primarily of autoimmune origin. Insulin
deficiency is severe, and provision of exogenous insulin is
required to minimize hyperglycemia and prevent ketoacidosis.
Insulin treatment in T1DM targets basal insulin needs and
nutrient ingestion. Individuals with T1DM are at increased risk
of other autoimmune diseases including hyper- and hypothy-
roidism, adrenal insufficiency, and Celiac disease.
Insulin secretory defects are now thought to underlie T2DM
development. Frequently, obesity and an insulin resistant state
place increased demands on β-cells. A compensatory increase
in insulin secretion occurs. As β-cells are “over-worked,” the
secretory defect(s) is unmasked, β-cells can no longer meet the
increased insulin requirements, and hyperglycemia ensues.
Treatment approaches vary from diet and exercise to address
obesity and insulin resistance, to use of medications that either
improve insulin sensitivity or insulin secretion, to insulin
replacement. Ketoacidosis is rare. Dyslipidemia, hypertension,Gastrointestinal
Incretin Secretion 
GIPGLP-1
-cell
insulin secretion
proliferation*
apoptosis*
Adipose Tissue
lipogenesis
sser extent amino acids stimulate GLP-1 and GIP secretions. GLP-1 and GIP
optosis and promote β-cell proliferation. GIP also promotes lipogenesis. GLP-1
Table 1
Comparison of CFRD with T1DM and T2DM.
T1DM T2DM CFRD
Clinical features
Overweight Low High Low
HTN Low High Low
Dyslipidemia Low High Low
Ketosis prone Common Uncommon Uncommon
Microvascular complications Common Common Common
Pathophysiology
Islets Autoimmune destruction Inherent β-cell defect Islet destruction due to exocrine tissue destruction
Potential β-cell defect
Amyloid Absent Present Present
Insulin status Complete insulin deficiency Insulin resistance Partial insulin deficiency
Relative insulin deficiency Episodes of insulin resistance
GLP-1 Normal Normal or decreased secretion Decreased secretion
Efficacy normal Improved secretion with PERT a
GIP Normal Normal or decreased secretion Near-normal secretion
Decreased efficacy
Hyperglucagonemia Absent Present Absent
Genetic predisposition HLAD3 and D4 TCF7L2 TCF7L2
a PERT = pancreatic enzyme replacement.
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tional metabolic conditions in T2DM.
Highlighting its complex nature, T2DM is considered a
polygenic disorder. Inheritance of multiple common gene
variants simultaneously increases the T2DM risk [6]. The
repertoire of genes recognized as playing a role in the
pathogenesis of T2DM has grown considerably as a result of
recent genome wide association studies. The function of many
such genes has yet to be established. Some appear to confer
insulin resistance while others appear to impact insulin secretion
including TCF7L2, CAPN10, HNF1B, FOXO1, WFS1, SGK1,
and KCNQ1 (reviewed by [7]).
The role of incretins in T2DMhas received increased attention
over the past decade. Reduced or absent GLP-1 responses [3,8]
and partially reversible reductions in GLP-1 potency [9] have
been described. Reductions in GIP have not been observed [8],
but β-cell sensitivity to GIP may be reduced [10]. With
continuous infusion of GLP-1 in subjects with T2DM, plasma
glucose and insulin secretion improve [11,12]. Excess glucagon
has also been invoked as a mediator of T2DM.
2. Cystic fibrosis related diabetes (CFRD)
Genetic defects of β-cell function, drug-induced diabetes
including transplant diabetes, and exocrine pancreatic disor-
ders, such as CFRD are classified by the ADA as “other forms
of diabetes” [13]. CFRD occurs most commonly in the setting
of severe CF mutations associated with exocrine pancreatic
insufficiency and is considered an insulin insufficient state,
although ketoacidosis is uncommon, Table 1.
Delayed and blunted insulin and C-peptide (product of
proteolytic processing of pro-insulin) secretion typify the
OGTT in CF patients even in the absence of CFRD [14–16],
Fig. 2. Abnormalities are more pronounced with worseningglycemic status [14,16,17]. Intravenous challenges to glucose
and other stimulatory agents reveal impaired first-phase insulin
and C-peptide secretion in CF [16], a phenomenon also seen in
T2DM. Basal insulin secretion is generally at least partially
preserved.
Unlike T1DM, β-cell damage in CF does not appear to be of
autoimmune origin [18]. Instead, according to the traditional
“collateral damage” model of CFRD, abnormal chloride
channel function results in thick viscous secretions that give
rise to obstructive damage to the exocrine pancreas. Progres-
sive fibrosis and fatty infiltration ensue and destroy islet
architecture. Immunohistochemical studies of islets from
patients with CFRD identified significantly reduced percent-
age of insulin-producing cells within islets when compared to
islets of non-CFRD patients and controls [19–21] — this
β-cell specific destruction characterizes T1DM. In contrast,
decreased glucagon secretion has been found in response to
OGTT and various other stimuli in subjects with CF and
worsening glucose tolerance [14,16], suggesting islet cell
destruction is not cell-selective and is linked to exocrine
pancreas fibrosis. In fact, a subsequent post-mortem study found
an overall decrease in islet number without specific reduction of
β-cell content. Perhaps even more importantly, despite their
limitations as retrospective studies, these post-mortem findings
highlighted the variability in β-cell mass and its lack of
correlation with the diagnosis of CFRD.
Given this lack of correlation between the quantification of
β-cell mass and the presence or absence of diabetes, additional
mechanisms for insulin secretion defects have been sought.
Mouse models suggest CFTR (cystic fibrosis transmembrane
regulator) may have a more direct role in β-cell dysfunction [22].
Islet amyloid deposition, a feature of T2DM but of neither T1DM
nor pancreatitis [23], has been identified post-mortem in adults
with CF but not those with NGT or controls [24]. The role of islet
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serve as a marker of endoplasmic reticulum stress or may play a
direct role in this stress [26,27].
A possible link has been found between CFRD and T1DM
genes associated with inflammation, such as tumor necrosis
factor [28]. Twin studies have found that the most strong
GWAS-implicated T2DM gene TCF7L2 confers even more
strongly the risk of CFRD [29].
Until recently, the role of incretins in CF has received
limited attention. Initially, normal basal GLP-1 and GIP levels
were observed across the spectrum of glucose tolerance in CF
[14], but GIP hypersecretion during OGTT was found in adults
without CFRD [30]. More recently, impaired GLP-1 and GIP
secretions were described in five adults with CF without CFRD,
although their glucose tolerance and peak insulin secretion were
not well-characterized [31]. Another study reported no differences
in GLP-1 or insulin responses to OGTT in adults with CF and
NGT, IGT, and in newly diagnosed CFRD compared to healthy
controls [32]. This study, however, had several methodological
concerns: 1) they evaluated responses to an oral glucose load and
not a mixed meal so impairments in fat- and protein-stimulated
incretin secretion would not have been detected, 2) they may have
missed peak incretin and insulin secretion— early measurements
are critical since individuals with CF have delayed and blunted
insulin secretion [33], and 3) they defined glucose tolerance by the
two hour plasma glucose but peak glucose was 179 ± 30 mg/dL
(9.9 + 1.7 mmol/L) in the NGT group suggesting that glucose
excursion was not completely normal in at least a subset, and 4)
they combined pancreatic exocrine sufficient and insufficient
subjects in the analyses. Germane to clinical care, pancreatic
enzyme replacement improves glucose excursion and GLP-1
secretion in response to a mixed meal (Fig. 3) [31].
As the CF population ages, the normal decline in β-cell
function that occurs in everyone with aging may allow underlying
β-cell abnormalities to become more prominent. This normal
decline coupled with compromised insulin secretory capacity maythen give rise to diabetes and in some cases may obscure the
distinction between T2DM and CFRD.2.1. Insulin deficiency vs. insulin resistance
Insulin deficiency is the primary defect in CFRD, but the
potential contribution of insulin resistance in CF has also been
explored. Insulin resistance may arise from decreased glucose
uptake by muscle (peripheral insulin resistance) and through
impaired suppression of hepatic glucose production (hepatic
insulin resistance) [34,35]. Normal peripheral sensitivity in
CFRD [36], increased peripheral but reduced hepatic insulin
sensitivity [37], decreased hepatic sensitivity [38], and decreased
peripheral insulin sensitivity [35] have all been observed in CF.
These mixed results likely reflect differences in methodology,
glucose categorization, and in the underlying state of health of the
study populations. Overall, the data suggest that insulin sensitivity
is preserved in CF patients who do not have diabetes [37], but
modest insulin resistance is present in the setting of CFRD.
As with T2DM, insulin resistance may unmask underlying
defects in insulin secretion in CF. Insulin resistance may worsen
with acute pulmonary exacerbation, chronic severe lung
disease, and glucocorticoid therapy [39]. Obesity (defined as
BMI N 30 kg/m2 in adults), common in T2DM, is now
reported in CF and may place an additional burden on the CF
endocrine pancreas. In the U.S. in 2011, median BMI among
adult males and females with CF (age N 19 y) was 22.1. The
University of Pittsburgh CF Center reported overweight in
13% and obesity in 7% of 233 children age 2–18 y followed at
their center [40]. The 2008–2009 European Cystic Fibrosis
Society Patient Registry reports maximum BMI N 30 in many
countries in Europe [41]. According to the 2011 Australian CF
Data Registry, nearly 43% of adult males with CF age N 30 years
had BMI N 25; thus, nearly half of adult men with CF are
overweight or obese [42].
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3.1. Morbidity/mortality
CFRD has been associated with a nearly 6-fold greater
mortality rate [43], and in the 1980's, only 25% of CFRD patients
survived to age 30 years compared to 60% of the nondiabetic
group [44]. Confirming data from the 1980's, CFRD has been
associated with decreased survival even more recently [45–49].
Promising, however, are data associating improvements inM
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Fig. 4. Mortality in CF subjects with and without CFRD, from Moran et al. [50]survival with early identification and treatment of CFRD from
the University ofMinnesota where annual screening was initiated
in the 1980's and more aggressive treatment was initiated in the
following years [50], Fig. 4.
3.2. Nutritional status
Decreases in BMI have been found in the years prior to
CFRD diagnosis [47], and lower BMI has been observed in
CFRD patients older than 15 years with the greatest differenceoint of decade)
. Blue line: males, red line: females; solid line: CFRD; dashed line: CFRD.
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et al. found that having glucose N 140 mg/dL (N7.8 mmol/L)
for ≥4.5% of the time during continuous glucose monitoring
(CGM) (n = 15) predicted greater declines in weight-Z (change
in weight-Z: −0.3 + 0.4 vs 0.1 + 0.2) and FEV1%-predicted
(change in FEV1-percent predicted: −6 ± 7 vs −2 ± 11) over
the previous year than a percentage time b 4.5% (n = 8) in
adolescents defined as having NGT or IGT by OGTT [51].
These findings suggest more subtle glucose abnormalities may
be clinically relevant in CF, but the extent to which these more
subtle abnormalities predict future decline after adjusting
for important factors such as baseline weight-Z, BMI-Z,
FEV1%-predicted, and pubertal status is not yet known and
the extent to which treatment of these glucose excursions
impacts CF-relevant outcomes has yet to be delineated.
Highlighting the role of insulin deficiency in nutritional status,
a randomized control trial identified improved BMI in adults
with CFRD without fasting hyperglycemia who were treated
with insulin for a year [52]. Smaller studies have found insulin
treatment improves weight in children with early insulin
deficiency, even prior to development of CFRD [53–55].
3.3. Pulmonary function
The presence of CFRD is linked to worse pulmonary
function regardless of age. The decline in clinical status can
occur in several years before the diagnosis of CFRD is made
[44,46,47]. The rate of pulmonary deterioration over a 4 year
period has been correlated with the degree of insulin deficiency
at baseline [46]. This finding reinforces the link between the loss
of the potent anabolic effects of insulin, subsequent protein
catabolism, and clinical deterioration [33], but hyperglycemia may
also play a direct role in this deterioration potentially through
oxidative stress. As found with nutritional status, studies of CGM
have identified greater declines in pulmonary function in children
with CF and greater daily glucose excursion even in the absence of
CFRD as defined by the OGTT [51]. Underscoring the role of
insulin in pulmonary function, insulin therapy may improve or
stabilize pulmonary function in the setting of pre-diabetes and
CFRD [56–58].
3.4. Microvascular complications
As in other forms of diabetes, microvascular complications
occur in CFRD. The risk appears associated with the presence
of fasting hyperglycemia: 16% of CFRD subjects with FH had
retinopathy and 14% had microalbuminuria while none in the
absence of fasting hyperglycemia had evidence of these
complications [59]. Diabetic nephropathy has been confirmed
histologically [60]. The prevalence is lower than with the other
forms of diabetes which may stem from shorter duration of
diabetes, better glycemic control, some persistence of endog-
enous insulin secretion, and absence of other metabolic risk
factors, such as dyslipidemia and hypertension [59], although
the landscape of CF is changing with both obesity [61,62] and
hypertension being more commonly reported as the population
ages [60]. In a much smaller group of 30 insulin treated CFRDsubjects, nine of whom had history of lung transplant, Andersen
et al., reported retinopathy in 27% [63]. Microalbuminuria in
this group was not common although hypertension and renal
impairment were found in the cyclosporine treated transplant
group [63].
Autonomic neuropathy and gastropathy do occur in CFRD
at similar rates to those found in T1DM [59]. Based upon the
above findings, annual microvascular complication screening
as occurs with T1DM is recommended in CFRD patients who
have had fasting hyperglycemia for 5 years or at diagnosis if
onset is not known [59]. Awareness should be heightened in
groups receiving chronic nephrotoxic drugs in the setting of
transplant.
3.5. Graft survival
Diabetes is also a well-recognized threat to overall survival
after solid organ transplantation [64,65], but data with respect
to transplant in CF and the pediatric population is limited and
the extent to which diabetes impacts graft survival (liver or
lung) in CF is not clear.
4. CFRD screening & diagnosis
Screening for CFRD has received increased attention over
the past few years. The motivation for aggressive screening
largely derives from the association of CFRD with negative
outcomes. Screening is recommended because CFRD onset is
usually insidious. Classical diabetes symptoms such as polyuria
and polydipsia may not be evident, and other symptoms such as
failure to gain or maintain weight, poor growth, and unexpected
pulmonary function decline [66] are nonspecific.
4.1. Oral glucose tolerance testing (OGTT)
The majority of patients with CFRD do not have fasting
hyperglycemia, and, in the absence of classic symptoms, the
diagnosis of CFRD frequently relies on the oral glucose tolerance
test (OGTT). As of 2010, annual screening for CFRD with an
OGTT (1.75 g/kg glucose as advocated by the World Health
Organization; maximum dose 75 g) starting at age 10 y was
recommended by the U.S. Cystic Fibrosis Foundation (CFF) [67]
and the International Society of Pediatric & Adolescent Diabetes
(ISPAD) [68]. The OGTT should also be performed prior to
transplant and during pregnancy. Based on the OGTT, four
glucose tolerance categories are defined:
Normal glucose tolerance (NGT) = one hour plasma glucose
(PG1) b 200 mg/dL (b11.1 mmol/L) and two hour plasma
glucose (PG2) b 140 mg/dL (b7.8 mmol/L)
Impaired glucose tolerance (IGT) = PG2 ≥ 140 and b200 mg/dL
(≥7.8 and b11.1 mmol/L)
CFRD = PG2 ≥ 200 mg/dL (≥11.1 mmol/L)
CFRD w/o fasting hyperglycemia (FH) = fasting PG b 126 mg/dL
(b7 mmol/L)
Table 2
Screening & diagnostic criteria for CFRD.
OGTT Interpretation of OGTT PG mg/dL (mmol/L)
•Healthy outpatients (OGTT is test of choice) Fasting PG 2-h PG 1-h PG
✓ Annually by age 10 y NGT b126 (b7) b140 (b7.8)
IGT b126 (b7) 140–199 (7.8–11)
•Prior to transplant CFRD ≥126 (≥7) ≥200 (≥11.1)
•Prior to planned pregnancy Indeterminate b126 (b7) b140 (b7.8) ≥200 (≥11.1)
•During pregnancy Gestational diabetes ≥92 (≥5.1) ≥153 (≥8.5) ≥180 (≥10)
Fasting and 2-h post-prandial glucose (PPG) monitoring
•During hospitalizations CFRD Fasting glucose ≥126 mg/dL (≥7 mmol/L)
•Outpatient PPG ≥ 200 mg/dL (≥11.1 mmol/L)
•During intercurrent illness, intravenous antibiotic use, or systemic
glucocorticoid use
Persisting N48 h during illness
•Monthly during and after continuous overnight enteral feeds ≥200 mg/dL (≥11.1 mmol/L) during/after feed
HbA1C CFRD ≥6.5% (b6.5 does not exclude CFRD)
Random glucose CFRD ≥200 mg/dL (≥11.1 mmol/L) + polyuria & polydipsia
ADAPTED FROM North American CF Consensus Committee 2010 [67].
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(b7 mmol/L)
Indeterminate glycemia (Ind-) = PG1 ≥ 200 mg/dL
(≥11.1 mmol/L) but PG2 b 140 mg/dL (b7.8 mmol/L).
Few patients have completely normal glucose tolerance. Early
glucose changes involve variable postprandial hyperglycemia,
occurring earlier than 2 h as evidenced by frequent elevations in
30-, 60-, and 90-minute plasma glucose duringOGTT [69], Fig. 2.
Moreover, with respect to the “new” category of Indeterminate
glycemia, recent data in non-CF suggests PG1 N 155 mg/dL
(N8.6 mmol/L) may not be completely normal; PG1 at this level
are a risk factor for T2DM development and are associated with
early atherosclerosis [70]. The clinical relevance of PG1 in this
lower range for CF is not known.
The CFF [67] and ISPAD [68] guidelines no longer
differentiate whether FH is present or absent. This original
distinction arose because at the time of the 1998 consensus
[43], limited data were available relating mild to moderate
hyperglycemia and risk of complications in CFRD and regarding
appropriateness of using conventional thresholds derived from
epidemiologic studies in non-CF patients [66] in whom glucose
concentrations associatedmicrovascular complications were used
to define diabetes. Newer data targeting CF-relevant outcomes
such as BMI and pulmonary function have provided evidence
supporting treatment of CFRD even in the absence of fasting
hyperglycemia [52]. Contrary to what one might expect, impaired
fasting glucose is not associated with worse survival, nutritional
status, pulmonary function, or progression to CFRD [71].
4.2. Random glucose monitoring
Measurement of fasting and postprandial glucose during
hospitalizations for acute illness is recommended [67,68].
Hyperglycemia persisting beyond 48 h in this setting is
consistent with the diagnosis of CFRD. The utility of formal
OGTT over these measures during hospitalization has not beenevaluated. In the outpatient setting, glucose should be measured
periodically during and after continuous overnight G-tube feeds
and should also be measured during intercurrent illnesses
requiring intravenous antibiotics or glucocorticoid treatment [39].
Implementation of annual CFRD screening with the OGTT
has been problematic for some individuals and centers, and the
utility of random or post-prandial glucose monitoring as
potentially more practical approach has been broached. The
current guidelines combine random plasma glucose N 200 mg/dL
(11.1 mmol/L) with the presence of symptoms (or during
hospitalization). Extending the use of random glucose to in-
dividuals in the well state is problematic: glucose ≥ 200 mg/dL
(11.1 mmol/L) is not uncommonly found at times earlier than 2 h
during the OGTT but is b200 mg/dL (11.1 mmol/L) by 2 h and
during continuous glucose monitoring. While these early glucose
increases are likely both abnormal and reflective of defective
insulin secretion, they are not synonymous with diabetes.
Insufficient evidence pairing random glucose concentrations with
either the OGTT or long-term outcomes is currently available to
extend the current diagnostic guidelines to include random/
post-prandial glucose N 200 mg/dL (11.1 mmol/L) in the absence
of symptoms. A similar issue arises in the diagnosis of Type 2
diabetes but in T2DM HbA1C and fasting glucose [5] are much
more useful alternatives than in CF.
Screening strategies for inpatient and outpatient care are
outlined in Table 2.4.3. Hemoglobin A1c
The majority of studies find HbA1c underestimates overall
glycemic control in CF patients compared with the non-CF
population. For instance, in one study, HbA1c was normal in
about 70% of CFRD cases diagnosed by OGTT [34]. Thus,
HbA1c is not recommended as a tool for CFRD screening.
Importantly, however, while a normal HbA1C does not exclude
CFRD, an HbA1C ≥ 6.5% is consistent with diabetes. A good
HbA1c may also be falsely reassuring in the management of
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spuriously low, it may still be useful for monitoring diabetes
control since an elevated HbA1C is consistent with increased
blood glucose and trends in HbA1c may still be followed.
4.4. Continuous glucose monitoring
CGM measures interstitial glucose which is then “translated”
as blood glucose. It has been validated in both CF and non-CF
patients and is frequently used to evaluate glucose trends in
T1DM. In CF, mean glucose levels higher than age-matched
controls have been identified by CGM [73], and postprandial
glucose peaks above 200 mg/dL (11.1 mmol/L) have been
observed in a third of CF subjects with NGT, half of IGT
subjects, and all patients with CFRD [42]. In 2010, Hameed et al.
found glucose N 140 mg/dL (N7.8 mmol/L) during CGM was
correlated with greater declines in weight-Z and pulmonary
function over the previous year in children defined as having
NGT or IGT by OGTT [51]. O'Riordan reported CGM results in
over 100 children with CF and found it to agree well with OGTT
and to be reproducible [74]. In an abstract presented at the 2012
North American CF Conference, CGM has been identified as a
useful tool in diagnosing and managing CFRD in adults with CF
[75]. While CGM was not recommended by the U.S. Cystic
Fibrosis Foundation as a diagnostic test for CFRD, it was
considered a complementary tool in the management of CFRD.
ISPAD extended the use of CGM as a potential adjunct to OGTT
in diagnosing CFRD [68]. Use of CGM as a diagnostic tool for
CFRD is receiving increasing attention. Glucose excursions
≥200 mg/dL (≥11.1 mmol/L) are well recognized in individ-
uals with CF in the absence of OGTT-defined CFRD just as these
same excursions are commonly found at 30-, 60-, and 90-min but
not at 120 min during OGTT.While these glucose excursions are
not normal, may explain declines in CF-relevant outcomes, and
may be worthy of treatment, the extent to which they can be
defined as CFRD has not been the subject of rigorous
investigation.
5. Prevalence/incidence
The number of patients diagnosed with CFRD is rapidly
increasing, possibly reflecting better surveillance and improved
survival. In fact, an Australian study identified a 10 times higher
incidence of CFRD (22.1 cases/1000 children and adolescents
with CF) following the introduction of annual screening [76]. Data
from the University ofMinnesota where annual OGTT screening
is recommended for all patients ≥ 6 years, find CFRD affects
2% of children, 19% of adolescents, and 40–50% of adults
[50]. A study that included 24 young Italian children (age 2–
5.9 years) with CF found 33% had varying degrees of glucose
intolerance ranging from Indeterminate-GT to CFRD [77]. A
15 year study of 775 patients ≥ 6 years identified CFRD
diagnosed by OGTT in over a third [59]. Within a 10 year
period, 60% of patients with CFRD without FH progressed to
CFRD with FH [59]. The annual incidence of CFRD is reported
to increase with age at 5.0%/year in patients 10 + years and 9.3%/
year in patients 20 + years [34]. At least in children, increasedplasma glucose at 1 h during an oral glucose tolerance test predicts
increased risk of progression to CFRD [78]. Other risk factors
include pancreatic insufficiency and family history of diabetes.
Post-transplant diabetes is considered a distinct clinical entity,
but, in the setting of CF, the etiology blurs. Stresses related to
transplant, including glucocorticoids and immunosuppression
with tacrolimus and cyclosporine [79–81], likely unmask the
underlying β-cell defects and diabetes becomes evident. In one
study, the diagnosis of CF increased the likelihood of diabetes
post-transplant three times and over 50% of transplant recipients
with CF developed diabetes post-transplant [82].
Gestational diabetes is not uncommon in the otherwise healthy
population, and women with CF appear to be at increased for
developing diabetes during pregnancy. The data regarding
incidence and maternal and fetal outcomes with respect to
CFRD, however, is limited.
Autoimmune T1DM can occur in the setting of cystic fibrosis.
In fact, in the study by Rana et al. reporting the incidence of CFRD
inAustralian children and adolescents, two childrenwere identified
as having T1DM over an eight year period (an additional 49 were
diagnosed with CFRD) [76]. The presence of diabetes autoanti-
bodies and higher insulin requirements were distinguishing
features. Distinguishing T1DM fromCFRD is clinically relevant;
T1DM greatly increases the risk of diabetic ketoacidosis and is
associated with other autoimmune disease (thyroid, primary
adrenal insufficiency) which may impact management.6. Treatment
Prior to the 2009 ISPAD and 2010 CFF guidelines, the
treatment of CFRD with FH was recommended and treatment
of CFRD without FH was recommended only in the presence of
symptoms. With newer data identifying a nutritional benefit,
treatment of CFRDwithout hyperglycemia is now recommended.
The role of treating pre-diabetes is now receiving increasing
attention [53,54,77]. The CFRD treatment of choice is insulin.
The insulin regimen is tailored to fit the individual patient.
Combinations of basal (long-acting) and bolus (rapid-acting)
insulins are used in the setting of fasting hyperglycemia.
Pre-meal rapid-acting insulin is the primary approach to the
treatment of CFRD without FH.
Basal insulin formulations such as glargine and detemir last
typically 18–24 h, are generally peakless, and are frequently
given once daily. NPH is also long-acting but the duration of
action is about 12 h, and a peak occurs around 6 h following
administration; this peak can be used to address food intake that is
normally planned for that time but can lead to hypoglycemia if
food is not ingested. Onset of action for rapid acting insulins
(aspart, lispro, apidra) is approximately 5 min with a peak action
at 90 min and a duration of action of 2–3 h making it an
appropriate insulin to target food intake [83,84]. Carbohydrate
coverage is typically started at 0.5–1 units of rapid-acting insulin
for every 15 g of carbohydrates consumed; this dose is refined to
achieve postprandial blood glucose goals [39]. Extra rapid-acting
insulin, the so-called “touch up” or “correction” dose may be
given pre-meal if hyperglycemia is present. Frequent meals are
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insulin pump often an ideal option [85,86].
With overnight continuous enteral feeds, a single injection
of NPH and regular insulin can be used to cover the ~8 h
“meal” [39]; with the initiation of this regimen blood glucose is
monitored periodically in the middle and at the end of the
enteral feeding to help with titration of insulin doses. During
intercurrent illness and systemic glucocorticoid use, insulin
needs can increase dramatically — frequently doubling and
even tripling.
Multiple daily injections may be rejected by some patients,
as demonstrated by the drop-out rate in a recent trial [52]. Once
daily detemir was associated with improved nutritional status in
six newly diagnosed children/adolescents with CFRD [53], but
no study has directly compared the risks and benefits of once
daily vs. bolus insulin regimens in either the early stages of
CFRD or as CFRD progresses. As highlighted by Hameed et al.
[53], these treatment burden considerations are extremely
important: insulin injections, blood glucose monitoring, and
even carbohydrate counting are additional medical burdens for
a population already undertaking multiple medical therapies.
Such interventions may be rejected or may impact adherence
with other therapies. Thus, in discussions with patients and their
families regarding treatment options, the lifestyle, eating habits,
physical activity, and potential barriers to insulin administration
and glucose monitoring must be considered. For individuals who
“graze,” who decline insulin injections with meals, in whom
adherence is an issue, or in whom a very simple approach is
desired, a combination 70/30 insulin may be useful. Some
individuals may only require insulin during overnight continuous
feeds, when the majority of carbohydrates are delivered. For
individuals who have minimal caloric intake at breakfast, insulin
therapy is delayed until the first meal of the day. Carbohydrate
counting, the mainstay of T1DM management, may be cumber-
some in the setting of CF, and set insulin doses may achieve good
glucose control, especially if the individual has consistent food
intake at meals when insulin is delivered. In the absence of an
insulin pump, insulin injections beyond 3 times per day can be
excessive, and the teammight focus on insulin delivery at the three
largest meals of the day.
Education regarding the etiology and implications of CFRD,
insulin therapy, blood glucose monitoring, treatment of hypo-
and hyperglycemia, and the effects of food intake, stress, illness,
and physical activity is crucial for successful partnership in the
management of CFRD. “Managing Cystic-Fibrosis-Related
Diabetes: An Instruction Guide for Parents and Families” is
available online from the CFF (http://www.cff.org/UploadedFiles/
LivingWithCF/StayingHealthy/Diet/Diabetes/CFRD-Manual-
5th%20Edition-05-2012.pdf).
Oral hypoglycemic agents are currently not recommended
for the treatment of CFRD [87] based upon limited data and
concerns about potential side effects such as diarrhea and appetite
changes (metformin, acarbose), osteoporosis and liver dysfunction
(thiazolidinediones), hypoglycemia (sulfonylureas, glinides), and
theoretical acceleration of β-cell loss (sulfonylureas, glinides).
Nutritional therapy is an integral part of both CF and CFRD
management. Individuals with CF often require 120–150% ormore of normal caloric intake for age and gender to maintain
body weight, and caloric restriction is not an option in the
treatment of CFRD. While carbohydrate ingestion in general is
not discouraged, avoidance of specific food items high in simple
sugars and low in nutritional value such as soda or sugar confection
is useful to decrease the glucose excursion. Consuming such foods
in combination with complex carbohydrates, protein, and fats may
“soften” this excursion. Glucose excursion also appears improved
when pancreatic enzymes are taken with the meal [31].
7. Hypoglycemia
The major barrier to achieving near-perfect blood glucose
control in the setting of diabetes is the risk of hypoglycemia. This
risk was clearly demonstrated in the Diabetes Control and
Complications Trial [88], and despite newer insulin formulations
and glucose monitoring tools hypoglycemia remains a reality for
individuals with diabetes. Occasional, mild hypoglycemia (symp-
toms of hypoglycemia that do not interfere with normal activities)
is anticipated in the setting of good diabetes control. This
hypoglycemia generally develops as a result of 1) excess insulin—
as a result of erratic absorption, increased sensitivity, or just
absolute excessive administration, 2) inadequate food intake or
absorption for amount of insulin administered, 3) exercise without
adequate reduction in insulin dose or increase in carbohydrate
intake or 4) alcohol consumption.
As with T1DM, hypoglycemia can occur in the setting of
treated CFRD. CF patients have normal hypoglycemia awareness,
and thus the risk of hypoglycemia is no greater in patients with
CFRD than in other patients receiving insulin therapy. In the first
three months of the “Cystic Fibrosis Related Diabetes Trial” mild
hypoglycemia was reported in 16% of subjects randomized to
pre-prandial lispro insulin [52]. Education reduced the frequency
of these episodes, but curiously over the course of the study, mild
hypoglycemia was also reported in the placebo group. Moreover,
fasting and reactive hypoglycemia have been reported in
approximately 6–15% of CF patients undergoing routine OGTT
[89,90], although the frequency may be less if the strict definition
of hypoglycemia (PG b 50 mg/dL, b2.8 mmol/L) is used [91,92].
In otherwise healthy individuals undergoing OGTT, the average
nadir glucose is 63 mg/dL (3.5 mmol/L) and 25% of subjects have
a nadir glucose of 55 mg/dL (3 mmol/L) or less; the majority of
the nadir blood glucose occurring at 3–4 h of the OGTT [93]. Thus
while hypoglycemia is reported in CF during OGTT, the frequency
does not appear more common than occurs in individuals without
CF. Moreover, PG b 60 mg/dL (b3.3 mmol/L) at 2 h during the
OGTT did not predict subsequent development of IGT or diabetes
in individuals with CF [90].
Glucagon is the body's major defense against insulin-induced
hypoglycemia. It stimulates glycogenolysis and gluconeogenesis.
In T1DM, glucagon secretion is generally lost after a few years;
in a subset of patients, epinephrine is also lost after 10–15 years
of T1DM. Loss of these counter-regulatory hormones in T1DM
as well as resetting of normal responses due to repeated
hypoglycemia can lead to hypoglycemia unawareness and severe
hypoglycemia. Glucagon secretion is also impaired in CFRD
[16]. While not yet reported, loss of epinephrine secretion after
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frequent hypoglycemia are not unexpected in CF.
Other causes of hypoglycemia might also be considered.
With fundoplication-related late dumping syndrome, hypogly-
cemia arises from exaggerated insulin secretion after a bolus
feed. Early hyperglycemia is a common finding, and, thus the
insulin and glycemic pattern can resemble that of a subject with
CF. Excessive secretion of GLP-1 has been implicated in the
excessive insulin secretion [94].
Fasting hypoglycemia can also occur in the setting of adrenal
insufficiency. This adrenal insufficiency might arise following
withdraw of a prolonged glucocorticoid use. Additionally,
adrenal crisis and hypoglycemia have been reported with
inhaled corticosteroid use [95–97]. Suppression of the
hypothalamic–pituitary–adrenal axis may be more common
with the combination of inhaled and nasal corticosteroids [98].
The combination of inhaled corticosteroids and fluconazole, a
CYP3A4 inhibitor, has been reported to cause Cushing
syndrome in a child with CF [99].
8. Psychosocial impact
The diagnosis of CFRD places additional treatment burden
upon an already cumbersome daily regimen for patients with CF.
Limited data is available on how individuals with CF cope with
the diagnosis of a second chronic illness, how CFRD affects
quality of life, or how the medical team can facilitate the
acceptance of the diagnosis and its intervention. As one might
imagine, initial reactions range from shock to relief [100]. Several
key messages from the interviews conducted by Collins and
Reynolds of adults diagnosed with CFRD are worth noting for
healthcare providers: the lack of awareness that diabetes develops
in CF was stressful for interviewees and better diabetes support
and education are desirable [100].
Given the attention now being paid to CFRD and recommen-
dations for annual screening, awareness of CFRD as a disease
entity is likely to have increased among patients with CF and their
families. Parent and family education events that include sessions
on CFRD may help improve this awareness. Availability of a
clinical team with expertise in CFRD, a CFRD-specific educa-
tional program, and educational materials (like those available
through the CFF) may also facilitate adapting to the diagnosis of
CFRD. Misconceptions that the diagnosis of CFRD translates into
caloric restriction are also common. Assuring patients that the
diabetes team does not seek to restrict calories is a key; calories
may need to be more evenly distributed through the day and
sugared-soda and pure sugar candies avoided or consumed in the
context of complex carbohydrate, protein and fat intake.Moreover,
the management of diabetes (as with T1DM) needs to be placed
into the context of one's daily life. A flexible approach to CFRD is
desirable; conforming one's daily activities around insulin dosing
is less than ideal.
9. Future perspectives
The mechanisms underlying insulin secretion defects and
the relationships of hyperglycemia and insulin deficiency to CFstatus are the subject of intense investigation as are diabetes
screening and the role of earlier treatment in β-cell preserva-
tion, nutritional status, and pulmonary function.
CFRD and impaired glucose tolerance are defined by the
two-hour plasma glucose during the OGTT. The standard 75 g
OGTT is performed in the fasting state and requires blood draws at
0 and 120 min, although many centers also obtain a glucose level
at 1 h. Adherence to recommendations to obtain an OGTT yearly
starting at 10 years has not been an idea— raising concerns that
the fasting requirement and time commitment are prohibitive for
some patients. An alternate test, such as the 50 g glucose
challenge test (GCT) may be more acceptable for some patients.
This test 1) has been used to screen for gestational diabetes and
more recently has been found to be useful in identifying
pre-diabetes and T2DM [101], 2) does not require fasting, and
3) relies on a single blood draw at 1 h. Such a test might be used
to identify the subset of individuals at greater risk of CFRD and
IGT and in whom the standard OGTT should be performed. A
multi-center study funded by the CF Foundation to address this
question is now being conducted (PI: Phillips at Emory).
Additional questions regarding screening include feasibility
of identifying a subset of subjects in whom performing OGTT
at less frequent intervals might be safe and appropriate.
The role of the earlier treatment of insulin deficiency and
glucose intolerance in CF is receiving increasing attentionwith the
main outcomes of interest, pulmonary function and BMI. A
one-year study of short acting-insulin at meals found no benefit to
BMI or pulmonary function in adults with CF and impaired
glucose tolerance [52], but was likely underpowered. In a
subsequent study that pre-selected a less healthy CF population,
glargine insulin at a dose of 0.15 units/kg/day did not impact
CF-relevant outcomes, but this dose of insulin has been
considered too low to provide anabolic benefit [102]. Hameed's
uncontrolled study of detemir insulin, 0.1 units/kg/day, however,
did identify improvements in nutritional status and pulmonary
function in children with pre-diabetes [53]. A follow-up
randomized trial of once daily detemir in children and adolescents
by this same group is ongoing (PI: Verge, Clinical Trials.gov
NCT01100892). Additional studies will hopefully better define
the role of earlier treatment. Such trials include an ongoing study
of sitagliptin, a medication that inhibits catabolism of incretins,
that is being trialed in CF-IGT (PI: Stecenko; ClinicalTrials.gov
NCT00967798). This treatment modality is particularly attractive
since incretin based therapy restores first phase insulin secretion in
T2DM [103] and increases β-cell number in animal models
[104–106]. Until the results of these or other definitive studies are
available, the routine use of insulin or other diabetes therapy for
the preservation of lung function, nutritional status, and β-cell
function in individuals with CF and early glucose abnormalities
cannot be recommended. However, in patients with deteriorating
pulmonary status who do not meet the current criteria for CFRD
but in whom glucose ≥ 200 mg/dL (11.1 mmol/L) has been
observed either post-prandially or during CGM, consideration
may be given to insulin therapy. This consideration should include
a frank discussion with the patient/family regarding the limited
and conflicting data that are available, additional burden, and risk
for hypoglycemia. The choice of insulin therapy, once-daily
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will require input from the patient and CF teammembers. The dose
of insulin required to secure an anabolic state without inducing
hypoglycemia is not known. The Diabetes Prevention Trial, a
study that aimed to prevent T1DM development in high-risk
individuals, used ultralente 0.125 units/kg BID (total daily dose
0.25 units/kg/day) without causing severe hypoglycemia [107];
weight gain over the course of the study was not described.
An extension of this question is how one defines early glucose
abnormalities in CF. A one hour plasma glucose N 200 mg/dL
(11.1 mmol/L) during the OGTT is defined as abnormal. Values
in the 140–200 mg/dL (7.8–11.1 mmol/L) range may not be
“normal,” but the clinical relevance of these values has yet to be
established. The one-hour plasma glucose has been associated
with lower FEV1%-predicted after adjustment for BMI, but the
relationship of the one-hour plasma glucose value to longitudinal
outcomes has not been established [108]. Hameed et al. identified
a correlation between the peak OGTT in non-CFRD children and
decline in pulmonary function in the previous year [51], but this
study did not adjust for potentially important covariates such as
age, baseline BMI, baseline FEV1%-predicted and the extent to
which this greater decline reflects higher plasma glucose vs
increasing age is not clear. In the otherwise healthy population, a
one hour plasma glucose N 150–155 mg/dL (N8.3–8.6 mmol/
L) during the OGTT is associated with increased likelihood of
progression and evidence of carotid atherosclerosis compared to
individuals with NGT and one hour plasma glucose less than this
threshold [70,109,110] — suggesting even those lower glucose
concentrations may be relevant.
The mechanisms underlying CFRD are also being further
explored. A direct role of the CF transmembrane conductance
regulator (CFTR, the site of the CF chloride channel defect) in the
development of CFRD has been posited. CFTR is expressed in
rat and pancreatic α- and β-cells [111,112], although it is much
more highly expressed in α-cells [112]. Unlike the CF knock-out
mouse, the ferret CF model displays early glucose and insulin
secretory abnormalities [113]. The finding of dysregulated
insulin secretion in the newborn ferret suggests a primary defect
in insulin secretion is operative that goes beyond the collateral
damage model. These and other animal models will serve as tools
for understanding the pathophysiology of CFRD.10. Conclusions
As the CF population ages and maintains good health, the
prevalence of CFRD is expected to increase and complications
such as micro and macrovascular disease may become more
evident. Understanding the impact of hyperglycemia and
insulin deficiency on these outcomes the impact of interrupting
progression diabetes on CF nutritional status, lung function
and survival are goals for the near future.References
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